[Evaluation of the effects of treatment of osteoporosis].
Christensen
Palle Mark
PM
Syddansk Universitet, Forskningsenheden for klinisk farmakologi. pmchristensen@health.sdu.dk
Sørensen
Henrik Ancher
HA
Vestergaard
Peter
P
D000368:Aged; D003362:Cost-Benefit Analysis; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use; D005260:Female; D005598:Fractures, Spontaneous / Q000209:etiology / Q000517:prevention & control*; D006620:Hip Fractures / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000209:etiology / Q000517:prevention & control*; D000068296:Risedronic Acid; D012307:Risk Factors
D000068296:Risedronic Acid; D012968:Etidronic Acid